Drug General Information
Drug ID	D0M0PY
Former ID	DPR000039
Drug Name	DX-890
Indication	Acute lung injury; Acute respiratory distress syndrome; Cystic fibrosis [ICD9: 277.0, 518.5, 518.82, 709.2; ICD10:E84, J80, L90.5]		Phase 2	[522003]
Company	Dyax Corp.
Structure		Download 2D MOL
CAS Number	CAS 10024-97-2
ChEBI ID	ChEBI:17045
SuperDrug ATC ID	N01AX13
SuperDrug CAS ID	cas=010024972
Target and Pathway
Target(s)	Leukocyte elastase	Target Info	Inhibitor	[536500]
KEGG Pathway	Transcriptional misregulation in cancer
	Systemic lupus erythematosus
Pathway Interaction Database	Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
	C-MYB transcription factor network
Reactome	Collagen degradation
	Degradation of the extracellular matrix
	Activation of Matrix Metalloproteinases
WikiPathways	Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
	Human Complement System
	Degradation of collagen
References
Ref 522003	ClinicalTrials.gov (NCT00455767) Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients. U.S. National Institutes of Health.
Ref 536500	Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.